Business Context and Reporting Period
This Form 8-K Current Report was filed by OvaScience, Inc. (noted as Tempest Therapeutics, Inc. in metadata) on June 7, 2013. The filing reports on corporate governance changes, specifically the election of a new director and the appointment of a new executive officer, as well as the results of the 2013 Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and personnel appointments.
Material Changes and Personnel Appointments
Director Election
- Mary Fisher was elected as a Class II Director, with a term expiring at the 2014 annual meeting.
- Compensation: Granted non-statutory stock options to purchase 13,098 shares at an exercise price of $14.00 per share (closing price on June 7, 2013). Options vest in 12 equal monthly installments.
- Future Grants: Eligible for an annual grant of options to purchase 4,448 shares following each annual meeting.
- Cash Fee: Annual board fee of $30,000.
- Background: Former CEO of Colorescience (formerly SkinMedica) and COO of Acorda Therapeutics.
Executive Appointment
- Christopher M. Lindblom was appointed Vice President of Finance and Treasurer, effective June 7, 2013.
- Compensation: Annual base salary of $240,000 with eligibility for an annual bonus of up to 30% of base salary.
- Equity: Granted stock options to purchase 93,846 shares at $14.00 per share. The options have a 10-year term, vesting 25% on June 7, 2014, and the remainder quarterly thereafter.
- Severance: In the event of termination without cause or resignation for good reason, he is eligible for six months of base salary and six months of health/dental premiums.
- Background: Former VP of Accounting and Financial Planning at Infinity Pharmaceuticals and previously held finance roles at Millennium Pharmaceuticals.
Annual Meeting Results
The 2013 Annual Meeting of Stockholders was held on June 7, 2013. A quorum of 14,691,018 shares (80.75% of eligible shares) was present.
- Director Elections: Harald Stock, Jonathan Tilly, and Christoph Westphal were re-elected as Class I Directors. Each received 14,688,918 votes "For" and 2,100 votes "Withheld."
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2013, with 14,691,018 votes "For" and zero votes against or abstaining.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, or contingencies beyond standard indemnification agreements for directors and employment agreements for officers.
Investor Verification Checklist
- Verify the current stock price relative to the $14.00 exercise price granted to Mary Fisher and Christopher M. Lindblom.
- Review the Non-Employee Director Compensation Policy (Exhibit 10.1) for details on future equity grants.
- Confirm the vesting schedules and acceleration provisions in Mr. Lindblom's employment agreement regarding change of control events.
- Check subsequent filings for any updates to the Board composition or executive team following these appointments.